TRIPLEX COLOR CARE

Primær information

  • Handelsnavn:
  • TRIPLEX COLOR CARE
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Medicinsk udstyr

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

Lokation

  • Fås i:
  • TRIPLEX COLOR CARE
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Ecolab
  • Autorisationsnummer:
  • 112053E
  • Sidste ændring:
  • 12-03-2018

Produktresumé

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr.

1907/2006

TRIPLEX COLOR CARE

112053E

1 / 13

PUNKT 1. IDENTIFIKATION AF STOFFET/ BLANDINGEN OG AF SELSKABET/ VIRKSOMHEDEN

1.1 Produktidentifikator

Produktnavn

TRIPLEX COLOR CARE

Produkt kode

112053E

Anvendelse af stoffet/det

kemiske produkt

Vaskeforstærker

Stoftype

Blanding

Kun til erhvervsmæssig brug.

Information om fortyndning

Ingen information om fortyndning angivet.

1.2 Relevante identificerede anvendelser for stoffet eller blandingen samt anvendelser, der

frarådes

Identificerede anvendelser

Hjælpestof (Ikke-oxyderende). Automatisk proces

Hjælpestof (Ikke-oxyderende). Semi-automatisk proces

Hjælpestof (Ikke-oxyderende). Manuel proces

Anbefalede begrænsninger i

brugen

Forbeholdt industriel og erhvervsmæssig brug.

1.3 Nærmere oplysninger om leverandøren af sikkerhedsdatabladet

Firma

Ecolab ApS

Høffdingsvej 36

2500 Valby, Danmark Tel +45 36 15 85 85

dk-customerservice@ecolab.com

1.4 Nødtelefon

Nødtelefon

36 15 85 85 (hverdage 8.00 - 16.00)

Giftinformationen tlf. nr.

82 12 12 12

Udstedelse-/revisionsdato

08.08.2016

Udgave

PUNKT 2. FAREIDENTIFIKATION

2.1 Klassificering af stoffet eller blandingen

Klassificering (FORORDNING (EF) Nr. 1272/2008)

Ikke et farligt stof eller blanding.

2.2 Mærkningselementer

Etikettering (FORORDNING (EF) Nr. 1272/2008)

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

2 / 13

Ikke et farligt stof eller blanding.

Tillægsmærkning:

Særlig mærkning af visse

blandinger

Sikkerhedsdatablad kan på anmodning rekvireres.

2.3 Andre farer

Ingen kendte.

PUNKT 3. SAMMENSÆTNING AF/ OPLYSNING OM INDHOLDSSTOFFER

3.2 Blandinger

Farlige komponenter

Kemisk betegnelse

CAS-Nr.

EF-Nr.

REACH No.

KlassificeringFORORDNING (EF) Nr.

1272/2008

Koncentration

2-propen-1-aminium, n,n-

dimethyl-n-2-propenyl-,

chloride, homopolymer

26062-79-3

Kronisk toksicitet for vandmiljøet.

Kategori 3; H412

>= 2.5 - < 5

2-phenoxyethanol

122-99-6

204-589-7

01-2119488943-21

Akut toksicitet Kategori 4; H302

Øjenirritation Kategori 2; H319

>= 1 - < 2.5

For den fuldstændige tekst af faresætningerne nævnt i dette punkt, se punkt 16.

PUNKT 4. FØRSTEHJÆLPSFORANSTALTNINGER

4.1 Beskrivelse af førstehjælpsforanstaltninger

I tilfælde af øjenkontakt

Skyl med rigeligt vand.

I tilfælde af hudkontakt

Skyl med rigeligt vand.

Ved indtagelse.

Skyl munden. Søg læge hvis symptomer opstår.

Hvis det indåndes

Søg læge hvis symptomer opstår.

4.2 Vigtigste symptomer og virkninger, både akutte og forsinkede

I afsnit 11 findes mere detaljerede oplysninger om helbredspåvirkninger og symptomer.

4.3 Angivelse af om øjeblikkelig lægehjælp og særlig behandling er nødvendig

Behandling

Ingen specifikke foranstaltninger identificeret.

PUNKT 5. BRANDBEKÆMPELSE

5.1 Slukningsmidler

Egnede slukningsmidler

Brandslukningsforanstaltningerne skal være hensigtsmæssige i

forhold til lokale omstændigheder og det omgivne miljø.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

3 / 13

Uegnede slukningsmidler

Ingen kendte.

5.2 Særlige farer i forbindelse med stoffet eller blandingen

Specifikke farer ved

brandbekæmpelse

Ikke brandfarligt eller brændbart.

Farlige

forbrændingsprodukter

Nedbrydningsprodukter kan omfatte de følgende materialer:

Carbonoxider

Nitrogenoxider (NOx)

Svovloxider

Fosforholdige oxider

5.3 Anvisninger for brandmandskab

Særlige personlige

værnemidler, der skal bæres

af brandmandskabet

: Brug personligt beskyttelsesudstyr.

Yderligere oplysninger

: Brandrester og forurenet brandslukningsvand skal bortskaffes i

henhold til de lokale regler.

PUNKT 6. FORHOLDSREGLER OVER FOR UDSLIP VED UHELD

6.1 Personlige sikkerhedsforanstaltninger, personlige værnemidler og nødprocedurer

Rådgivning for ikke-

indsatspersonel

Der henvises til beskyttelsesforanstaltninger nævnt i afsnit 7 og 8.

Rådgivning for

indsatspersonel

Hvis særlig beklædning er påkrævet for at håndtere spildet, skal

man være opmærksom på alle oplysninger i punkt 8 om passende

og upassende materialer.

6.2 Miljøbeskyttelsesforanstaltninger

Miljøbeskyttelsesforanstaltnin

Ingen specielle miljømæssige forholdsregler kræves.

6.3 Metoder og udstyr til inddæmning og oprensning

Metoder til oprydning

Stands lækagen, hvis dette er sikkert.Opbevar og opsaml spild

med ikke brændbart absorberende materiale, (f. eks. sand, jord,

moler el. vermikulit) og placer det i affaldsbeholdere i henhold til

de lokale myndigheders forskrifter (se afsnit 13).Skyl rester væk

med vand.Ved store spild, inddæm det spildte materiale eller saml

det op på anden vis, for at sikre at spild ikke når vandveje.

6.4 Henvisning til andre punkter

Se Afsnit 1 for kontaktoplysninger i nødsituationer.

For personlig beskyttelse se punkt 8.

Se Afsnit 13 for yderligere oplysninger om affaldshåndtering.

PUNKT 7. HÅNDTERING OG OPBEVARING

7.1 Forholdsregler for sikker håndtering

Råd om sikker håndtering

Vask hænder efter håndtering. For personlig beskyttelse se punkt

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

4 / 13

Hygiejniske foranstaltninger

Vask hænder før pauser og straks efter håndtering af produktet.

7.2 Betingelser for sikker opbevaring, herunder eventuel uforenelighed

Krav til lager og beholdere

Opbevares utilgængeligt for børn. Hold beholderen tæt lukket.

Opbevares i behørigt mærkede beholdere.

Opbevaringstemperatur

0 °C til 40 °C

7.3 Særlige anvendelser

Særlige anvendelser

Hjælpestof (Ikke-oxyderende). Automatisk proces

Hjælpestof (Ikke-oxyderende). Semi-automatisk proces

Hjælpestof (Ikke-oxyderende). Manuel proces

PUNKT 8. EKSPONERINGSKONTROL/PERSONLIGE VÆRNEMIDLER

8.1 Kontrolparametre

Indeholder ingen stoffer med grænseværdi for erhvervsmæssig eksponering.

8.2 Eksponeringskontrol

Passende tekniske foranstaltninger

Tekniske foranstaltninger

God generel ventilation skulle være tilstrækkeligt til at kontrollere

arbejdernes udsættelse for luftbårne urenheder.

Individuelle beskyttelsesforanstaltninger

Hygiejniske foranstaltninger

Vask hænder før pauser og straks efter håndtering af produktet.

Beskyttelse af øjne / ansigt

(EN 166)

Intet specielt beskyttelsesudstyr nødvendigt.

Beskyttelse af hænder (EN

374)

Intet specielt beskyttelsesudstyr nødvendigt.

Beskyttelse af hud og krop

(EN 14605)

Intet specielt beskyttelsesudstyr nødvendigt.

Åndedrætsværn (EN 143,

14387)

Ingen påkrævet, hvis luftbårne koncentrationer holdes under de

oplyste grænseværdier for eksponering. Brug certificerede

åndedrætsværn der opfylder EU-krav (89/656 / EØF, 89/686 /

EØF) eller tilsvarende, når respiratoriske risici ikke kan undgås

eller i tilstrækkelig grad begrænses ved kollektive tekniske

beskyttelsesforanstaltninger eller ved foranstaltninger, metoder

eller procedurer i tilrettelæggelse af arbejdet.

Foranstaltninger til begrænsning af eksponering af miljøet

Generelle anvisninger

: Overvej om det er nødvendig at lukke opbevaringsbeholderne

inde.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

5 / 13

PUNKT 9. FYSISKE OG KEMISKE EGENSKABER

9.1 Oplysninger om grundlæggende fysiske og kemiske egenskaber

Udseende

: væske

Farve

: lysegul

Lugt

: som amin

pH-værdi

6.0 - 8.0, 100 %

Flammepunkt

Ikke anvendelig

Lugttærskel

Ikke anvendelig og/eller ikke bestemt for blandingen

Smeltepunkt/frysepunkt

Ikke anvendelig og/eller ikke bestemt for blandingen

Begyndelseskogepunkt og

kogepunktsinterval

Ikke anvendelig og/eller ikke bestemt for blandingen

Fordampningshastighed

Ikke anvendelig og/eller ikke bestemt for blandingen

Antændelighed (fast stof,

luftart)

Ikke anvendelig og/eller ikke bestemt for blandingen

Højeste eksplosionsgrænse

Ikke anvendelig og/eller ikke bestemt for blandingen

Laveste eksplosionsgrænse

Ikke anvendelig og/eller ikke bestemt for blandingen

Damptryk

Ikke anvendelig og/eller ikke bestemt for blandingen

Relativ dampvægtfylde

Ikke anvendelig og/eller ikke bestemt for blandingen

Relativ massefylde

1.0 - 1.096

Vandopløselighed

opløselig

Opløselighed i andre

opløsningsmidler

Ikke anvendelig og/eller ikke bestemt for blandingen

Fordelingskoefficient: n-

oktanol/vand

Ikke anvendelig og/eller ikke bestemt for blandingen

Selvantændelsestemperatur

Ikke anvendelig og/eller ikke bestemt for blandingen

Termisk spaltning

Ikke anvendelig og/eller ikke bestemt for blandingen

Viskositet, kinematisk

7.647 mm2/s (40 °C)

Eksplosive egenskaber

Ikke anvendelig og/eller ikke bestemt for blandingen

Oxiderende egenskaber

Stoffet eller blandingen er ikke klassificeret som oxiderende.

9.2 Andre oplysninger

Ikke anvendelig og/eller ikke bestemt for blandingen

PUNKT 10. STABILITET OG REAKTIVITET

10.1 Reaktivitet

Ingen farlige reaktioner kendt ved normalt brug under normale forhold.

10.2 Kemisk stabilitet

Stabil under normale forhold.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

6 / 13

10.3 Risiko for farlige reaktioner

Ingen farlige reaktioner kendt ved normalt brug under normale forhold.

10.4 Forhold, der skal undgås

Ingen kendte.

10.5 Materialer, der skal undgås

Ingen kendte.

10.6 Farlige nedbrydningsprodukter

Nedbrydningsprodukter kan omfatte de følgende materialer:

Carbonoxider

Nitrogenoxider (NOx)

Svovloxider

Fosforholdige oxider

PUNKT 11. TOKSIKOLOGISKE OPLYSNINGER

11.1 Oplysninger om toksikologiske virkninger

Oplysninger om sandsynlige

eksponeringsveje

Indånding, Øjenkontakt, Hudkontakt

Produkt

Akut oral toksicitet

: Estimat for akut toksicitet : > 2,000 mg/kg

Akut toksicitet ved indånding

: Der er ingen tilgængelige data på dette produkt.

Akut dermal toksicitet

: Der er ingen tilgængelige data på dette produkt.

Hudætsning/-irritation

: Der er ingen tilgængelige data på dette produkt.

Alvorlig

øjenskade/øjenirritation

: Der er ingen tilgængelige data på dette produkt.

Respiratorisk sensibilisering

eller hudsensibilisering

: Der er ingen tilgængelige data på dette produkt.

Kræftfremkaldende

egenskaber

: Der er ingen tilgængelige data på dette produkt.

Reproduktionsskadende

virkninger

: Der er ingen tilgængelige data på dette produkt.

Kimcellemutagenicitet

: Der er ingen tilgængelige data på dette produkt.

Fosterbeskadigelse

: Der er ingen tilgængelige data på dette produkt.

Enkel STOT-eksponering

: Der er ingen tilgængelige data på dette produkt.

Gentagne STOT-

: Der er ingen tilgængelige data på dette produkt.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

7 / 13

eksponeringer

Aspiration giftighed

: Der er ingen tilgængelige data på dette produkt.

Komponenter

Akut oral toksicitet

: 2-propen-1-aminium, n,n-dimethyl-n-2-propenyl-, chloride,

homopolymer

LD50 Rotte: 3,000 mg/kg

2-phenoxyethanol

LD50 Rotte: 2,000 mg/kg

Komponenter

Akut toksicitet ved indånding

: 2-propen-1-aminium, n,n-dimethyl-n-2-propenyl-, chloride,

homopolymer

4 h LC50 Rotte: > 20 mg/l

Komponenter

Akut dermal toksicitet

: 2-phenoxyethanol

LD50 Kanin: 2,250 mg/kg

Potentielle sundhedspåvirkninger

Øjne

Helbredsskader er ikke kendte eller forventede ved normalt brug.

Helbredsskader er ikke kendte eller forventede ved normalt brug.

Indtagelse

Helbredsskader er ikke kendte eller forventede ved normalt brug.

Indånding

Helbredsskader er ikke kendte eller forventede ved normalt brug.

Langtidspåvirkning

Helbredsskader er ikke kendte eller forventede ved normalt brug.

Erfaringer med human eksponering

Øjenkontakt

Ingen kendte eller forventede symptomer.

Hudkontakt

Ingen kendte eller forventede symptomer.

Indtagelse

Ingen kendte eller forventede symptomer.

Indånding

Ingen kendte eller forventede symptomer.

PUNKT 12. MILJØOPLYSNINGER

12.1 Økotoksicitet

Miljøpåvirkninger

Dette produkt har ingen kendt økotoksikologisk effekt.

Produkt

Toksicitet overfor fisk

: Ingen data tilgængelige

Toksicitet for dafnier og

andre hvirvelløse vanddyr.

: Ingen data tilgængelige

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

8 / 13

Toksicitet overfor alger

: Ingen data tilgængelige

Komponenter

Toksicitet overfor fisk

: 2-propen-1-aminium, n,n-dimethyl-n-2-propenyl-, chloride,

homopolymer

96 h LC50 Fisk: > 10 mg/l

2-phenoxyethanol

96 h LC50 Fisk: > 220 mg/l

12.2 Persistens og nedbrydelighed

Produkt

Biologisk nedbrydelighed

: Tensiderne i produktet er biologisk nedbrydelige iht. kravene i

forordning nr. 648/2004 om vaske- og rengøringsmidler.

Komponenter

Biologisk nedbrydelighed

2-propen-1-aminium, n,n-dimethyl-n-2-propenyl-, chloride,

homopolymer

Resultat: Ikke let bionedbrydeligt

2-phenoxyethanol

Resultat: Let bionedbrydeligt.

12.3 Bioakkumuleringspotentiale

Ingen data tilgængelige

12.4 Mobilitet i jord

Ingen data tilgængelige

12.5 Resultater af PBT- og vPvB-vurdering

Produkt

Vurdering

Dette stof/blanding indeholder ingen komponenter, der anses for

at være enten persistente, bioakkumulerende og toksiske (PBT)

eller meget persistente og meget bioakkumulerende (vPvB) ved

niveauer på 0.1% eller højere.

12.6 Andre negative virkninger

Ingen data tilgængelige

PUNKT 13. BORTSKAFFELSE

Bortskaffes i overensstemmelse med EU-direktiverne om affald og farligt affald.Affaldskoder skal

fastsættes af bruger, at fortrække i samarbejde med de myndigheder der er ansvarlig for

bortskaffelse af affald.

13.1 Metoder til affaldsbehandling

Produkt

: Fortyndet produkt kan skylles til sanitære kloaksystem

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

9 / 13

Forurenet emballage

: Bortskaffes i overensstemmelse med lokale, regionale og

nationale bestemmelser.

Vejledning til valg af

affaldskoder

: Organisk affald indeholdende farlige stoffer. Hvis dette produkt

anvendes i yderligere processer, skal den endelige bruger

omdefinere og tildele den mest hensigtsmæssige Europæiske

Affaldskatalogkode (EAK). Det påhviler den der producerer

affaldet at bestemme toksicitet og fysiske egenskaber af

materialet som genereres for at identificere affaldet korrekt og

bestemme bortskaffelsemetoder af affaldet i overensstemmelse

med gældende europæisk (EU direktiv 2008/98 / EF) og lokale

bestemmelser.

PUNKT 14. TRANSPORTOPLYSNINGER

Afsenderen har ansvar for, at emballager, etikettering og mærkning er i overensstemmelse med den

valgte transportform.

Vejtransport (ADR/ADN/RID)

14.1 FN-nummer

Ikke farligt gods

14.2 UN-

forsendelsesbetegnelse (UN

proper shipping name)

Ikke farligt gods

14.3 Transportfareklasse( r )

Ikke farligt gods

14.4 Emballagegruppe

Ikke farligt gods

14.5 Miljøfarer

Ikke farligt gods

14.6 Særlige

forsigtighedsregler for

brugeren

Ikke farligt gods

Lufttransport (IATA)

14.1 FN-nummer

Ikke farligt gods

14.2 UN-

forsendelsesbetegnelse (UN

proper shipping name)

Ikke farligt gods

14.3 Transportfareklasse( r )

Ikke farligt gods

14.4 Emballagegruppe

Ikke farligt gods

14.5 Miljøfarer

Ikke farligt gods

14.6 Særlige

forsigtighedsregler for

brugeren

Ikke farligt gods

Søtransport (IMDG/IMO)

14.1 FN-nummer

Ikke farligt gods

14.2 UN-

forsendelsesbetegnelse (UN

proper shipping name)

Ikke farligt gods

14.3 Transportfareklasse( r )

Ikke farligt gods

14.4 Emballagegruppe

Ikke farligt gods

14.5 Miljøfarer

Ikke farligt gods

14.6 Særlige

forsigtighedsregler for

Ikke farligt gods

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

10 / 13

brugeren

14.7 Bulktransport i henhold

til bilag II til MARPOL 73/78

og IBC-koden

Ikke farligt gods

PUNKT 15. OPLYSNINGER OM REGULERING

15.1 Særlige bestemmelser/særlig lovgivning for stoffet eller blandingen med hensyn til

sikkerhed, sundhed og miljø

iht. Detergent Forordningen

EU 648/2004

Andre bestanddele: Enzymer

Konserveringsmidler:

2-phenoxyethanol

National lovgivning

Vær opmærksom på Dir 94/33/EF til beskyttelse af unge mennesker på arbejde.

Produktregister nummer

2400236

15.2 Kemikaliesikkerhedsvurdering

Produktet indeholder stoffer, for hvilke der fortsat kræves en kemisk sikkerhedsvurdering.

PUNKT 16. ANDRE OPLYSNINGER

Fuld tekst af H-sætninger

H302

Farlig ved indtagelse.

H319

Forårsager alvorlig øjenirritation.

H412

Skadelig for vandlevende organismer, med langvarige virkninger.

Fuld tekst af andre forkortelser

ADN - Europæisk konvention om international transport af farligt gods ad indre vandveje; ADR -

Europæisk konvention om international transport af farligt gods ad vej; AICS

- Australiens

fortegnelse over kemiske stoffer; ASTM - Det amerikanske forbund for testning af materialer,

ASTM; bw - Kropsvægt; CLP - CLP-forordningen om klassificering, mærkning og emballering;

Forordning (EF) Nr. 1272/2008; CMR - Kræftfremkaldende, mutagent eller reproduktionstoksisk

stof; DIN - Standard fra det tyske standardiseringsinstitut; DSL - Liste over indenlandske stoffer

(Canada);

ECHA

europæiske

kemikalieagentur;

EC-Number

EU-nummer;

Koncentration forbundet med x % respons; ELx - Belastningsgrad forbundet med x % respons;

EmS - Nødplan; ENCS - Eksisterende og nye kemiske stoffer (Japan); ErCx - Koncentration

forbundet med x % vækstrate respons; GHS - Det globale harmoniserede system; GLP - God

laboratoriepraksis;

IARC

Internationale

Agentur

Kræftforskning;

IATA

Internationale Luftfartssammenslutning, IATA; IBC - Den internationale kode for konstruktion og

udrustning af skibe, som fører farlige kemikalier i bulk; IC50 - Halv maksimal inhiberende

koncentration; ICAO - Organisationen for International Civil Luftfart, ICAO; IECSC - Fortegnelse

over eksisterende kemikalier i Kina; IMDG - Det internationale regelsæt for søtransport af farligt

gods; IMO - Den Internationale Søfartsorganisation; ISHL - Lov om industriel sikkerhed og

sundhed (Japan); ISO - International standardiseringsorganisation; KECI - Koreas fortegnelse

over eksisterende kemikalier; LC50 - Dødelig koncentration for 50 % af en testpopulation; LD50 -

Dødelig dosis for 50 % af en testpopulation (gennemsnitlig dødelig dosis); MARPOL - Den

internationale konvention om forebyggelse af forurening fra skibe; n.o.s. - Andet ikke angivet;

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

11 / 13

NO(A)EC - Koncentration for ingen observeret (negativ) virkning; NO(A)EL - Niveau for ingen

observeret (negativ) virkning; NOELR - Belastningsgrad for ingen observeret virkning; NZIoC -

New Zealands fortegnelse over kemikalier; OECD - Organisationen for Økonomisk Samarbejde

og Udvikling; OPPTS - Afdelingen for kemisk sikkerhed og forebyggelse af forurening; PBT -

Persistent, bioakkumulativt og giftigt stof; PICCS - Fillippinernes fortegnelse over kemikalier og

kemiske stoffer; (Q)SAR - (Kvantitativt) forhold mellem struktur og aktivitet; REACH - Europa-

parlamentets og Rådets forordning (EF) nr. 1272/2008 om registrering, vurdering og godkendelse

af samt begrænsninger for kemikalier; RID - Reglement for international befordring af farligt gods

med jernbane; SADT - Selvaccelererende dekompositionstemperatur; SDS - Sikkerhedsdatablad;

TCSI - Taiwans fortegnelse over kemiske stoffer; TRGS - Teknisk forskrift for farlige stoffer; TSCA

- Lov om kontrol af giftige stoffer (USA); UN - Forenede Nationer; vPvB - Meget persistent og

meget bioakkumulativ

Udarbejdet af

Regulatory Affairs

Tal angives i sikkerhedsdatabladet i følgende form: 1,000,000 = 1 million og 1,000 = 1 tusind. 0.1

= 1 tiendedel og 0.001 = 1 tusindedel.

REVIDERET INFORMATION: Signifikante ændringer i den regulatoriske eller sundhedsmæssige

information af denne revision er angivet med en lodret streg i sikkerhedsdatabladets venstre

margin.

Informationerne i dette Arbejdshygiejniske Datablad er efter vor bedste viden, oplysninger og

overbevisning korrekte på datoen, hvor det er trykt. Informationerne tjener kun som vejledning til

sikker håndtering, brug, forarbejdning, lagring, transport, disponering og frigivelse og kan ikke

betragtes som en garanti eller kvalitetsangivelse. Informationerne vedrører kun det udtrykkeligt

angivne materiale og er ikke gældende for dette materiale anvendt i kombination med andre

materialer eller forarbejdning, medmindre udtrykkeligt anført i teksten.

BILAG: EKSPONERINGSSCENARIER

DPD+-stoffer

:

Følgende stoffer er de vigtigste stoffer der bidrager til blandingens eksponeringsscenarie i henhold

til DPD+-regelen:

Måde for

optagelse

Stof

CAS-Nr.

EINECS-Nr.

Indtagelse

2-phenoxyethanol

122-99-6

204-589-7

Indånding

Ikke afhængighedsstof

Ikke afhængighedsstof

Øjne

2-phenoxyethanol

122-99-6

204-589-7

vandmiljø

2-propen-1-aminium, n,n-dimethyl-n-2-

propenyl-, chloride, homopolymer

26062-79-3

Fysikaliske egenskaber DPD+-stoffer:

Stof

Damptryk

Vandopløselighe

d

Pow

Molar masse

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

12 / 13

2-phenoxyethanol

0.021 HPa

28.6 g/l

15.85

For at beregne om anvendelsesforholdene og de nødvendige risikohåndteringsforanstaltninger

er sikre, venligst kalkuler risikofaktor på dette web site:

www.ecetoc.org/tra

Eksponeringsscenariets korte

titel

Hjælpestof (Ikke-oxyderende). Automatisk proces

Use descriptors

Hovedbrugergrupper

Industrielle anvendelser: Anvendelser af stoffer som sådan eller i

kemiske produkter på industri-anlæg

Slutanvendelsessektor

SU3: Industrielle anvendelser: Anvendelser af stoffer som sådan

eller i kemiske produkter på industri-anlæg

Proceskategorier

PROC2: Anvendelse i lukket, kontinuerlig proces med kontrolleret

lejlighedsvis eksponering

PROC8b: Overførsel af stof eller kemisk produkt (påfyldning/

tømning) fra/ til kar/ store beholdere på dedikerede anlæg

Produktkategorier

PC35: Vaske- og renseprodukter (herunder opløsnings-

middelbaserede produkter)

Miljøudledningskategorier

ERC4: Industriel anvendelse i pro-cesser og produkter af pro-

ceshjælpemidler, der ikke bliver en del af artikler

Eksponeringsscenariets korte

titel

Hjælpestof (Ikke-oxyderende). Semi-automatisk proces

Use descriptors

Hovedbrugergrupper

Faglige anvendelser: Det offentlige område (administration,

uddannelse, forlystelser, tjeneste-ydelser, håndværkere)

Slutanvendelsessektor

SU22: Faglige anvendelser: Det offentlige område (administration,

uddannelse, forlystelser, tjeneste-ydelser, håndværkere)

Proceskategorier

PROC1: Anvendelse i lukket proces, ingen sandsynlighed for

eksponering

PROC8a: Overførsel af stof eller kemisk produkt (påfyldning/

udtømning) fra/ til kar/ store beholdere på ikke-dedikerede anlæg

Produktkategorier

PC35: Vaske- og renseprodukter (herunder opløsnings-

middelbaserede produkter)

Miljøudledningskategorier

ERC8b: Udbredt indendørs anvendelse af reaktive stoffer i åbne

systemer

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

TRIPLEX COLOR CARE

112053E

13 / 13

Eksponeringsscenariets korte

titel

Hjælpestof (Ikke-oxyderende). Manuel proces

Use descriptors

Hovedbrugergrupper

Faglige anvendelser: Det offentlige område (administration,

uddannelse, forlystelser, tjeneste-ydelser, håndværkere)

Slutanvendelsessektor

SU22: Faglige anvendelser: Det offentlige område (administration,

uddannelse, forlystelser, tjeneste-ydelser, håndværkere)

Proceskategorier

PROC4: Anvendelse i batch- eller anden proces (syntese) med

mulighed for eksponering

PROC8a: Overførsel af stof eller kemisk produkt (påfyldning/

udtømning) fra/ til kar/ store beholdere på ikke-dedikerede anlæg

Produktkategorier

PC35: Vaske- og renseprodukter (herunder opløsnings-

middelbaserede produkter)

Miljøudledningskategorier

ERC8a: Udbredt indendørs anvendelse af proceshjælpemidler i

åbne systemer

  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.



  • Dokumenter på andre sprog er tilgængelige her

5-10-2018

FDA allows marketing of first self-fitting hearing aid controlled by the user

FDA allows marketing of first self-fitting hearing aid controlled by the user

FDA allows marketing of a new device, the Bose Hearing Aid, intended to amplify sounds for individuals 18 years or older with perceived mild to moderate hearing impairment (hearing loss). This is the first hearing aid authorized for marketing by the FDA that enables the user to fit, program and control the hearing aid on his or her own, without assistance from a health care provider.

FDA - U.S. Food and Drug Administration

26-9-2018

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Published on: Tue, 25 Sep 2018 00:00:00 +0200 Abstract Following a notification from Sorghum Zrt., submitted to the European Commission under Article 14 of Regulation (EU) 2015/2283 to place on the market syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country (TF), and in line with Article 15(2) of that Regulation, EFSA was asked by the European Commission whether there are duly reasoned safety objections to the placing on the market of the TF within the European Union. The ap...

Europe - EFSA - European Food Safety Authority Publications

25-9-2018

September 24, 2018: Board Certified Ophthalmologist Agrees to Civil Fraud Settlement in Medicare Fraud Investigation

September 24, 2018: Board Certified Ophthalmologist Agrees to Civil Fraud Settlement in Medicare Fraud Investigation

September 24, 2018: Board Certified Ophthalmologist Agrees to Civil Fraud Settlement in Medicare Fraud Investigation

FDA - U.S. Food and Drug Administration

20-9-2018

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Health Canada's sampling and evaluation program has determined that the rubber animals do not meet the Canadian safety requirements for toys. The squeakers inside the rubber animals can be easily removed; these small parts pose a choking hazard to young children.

Health Canada

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

17-9-2018

September 11, 2018: Columbus Pharmacist Sentenced for Health Care Fraud Scheme

September 11, 2018: Columbus Pharmacist Sentenced for Health Care Fraud Scheme

September 11, 2018: Columbus Pharmacist Sentenced for Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

28-8-2018

Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle

Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle

Pfizer Consumer Healthcare, a division of Pfizer Inc., is voluntarily recalling one lot of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle because of customer complaints that the dosage cup provided is marked in teaspoons and the instructions on the label are described in milliliters (mL).

FDA - U.S. Food and Drug Administration

28-8-2018

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

A 100 count bottle of Hydrochlorothiazide Tablets USP 12.5 mg has been found to contain 100 Spironolactone Tablets USP 25 mg. Since the individual lot, PW05264, of the product is involved in a potential mix-up of labeling, Accord is recalling this individual lot from the market.

FDA - U.S. Food and Drug Administration

22-8-2018

FDA approves first drug for neurotrophic keratitis, a rare eye disease

FDA approves first drug for neurotrophic keratitis, a rare eye disease

FDA approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).

FDA - U.S. Food and Drug Administration

17-8-2018

Temporary Total Artificial Heart Companion 2 Driver System by SynCardia Systems: Letter to Health Care Providers - Risk of Mortality and Stroke

Temporary Total Artificial Heart Companion 2 Driver System by SynCardia Systems: Letter to Health Care Providers - Risk of Mortality and Stroke

FDA has reviewed the final results from the post-approval study conducted by SynCardia Systems, LLC. for their Temporary Total Artificial Heart (TAH-t) Companion 2 Driver System (C2 Driver System). These final results indicate a higher mortality rate and higher stroke rate for patients initially supported with the C2 Driver System compared to patients initially supported with the previous generation driver, the Circulatory Support System (CSS) Console.

FDA - U.S. Food and Drug Administration

16-8-2018

August 16, 2018: Genesee County Physician and Two Others Charged with Health Care Fraud

August 16, 2018: Genesee County Physician and Two Others Charged with Health Care Fraud

August 16, 2018: Genesee County Physician and Two Others Charged with Health Care Fraud

FDA - U.S. Food and Drug Administration

8-8-2018

Risks Associated with Use of Rupture of Membranes Tests - Letter to Health Care Providers

Risks Associated with Use of Rupture of Membranes Tests - Letter to Health Care Providers

The FDA is reminding health care providers that tests to detect rupture of the amniotic membranes should not be used without other clinical assessments to make critical patient management decisions.

FDA - U.S. Food and Drug Administration

8-8-2018

FDA alerts healthcare providers, women about risks associated with improper use of rupture of membranes tests

FDA alerts healthcare providers, women about risks associated with improper use of rupture of membranes tests

FDA alerts healthcare providers, women about risks associated with improper use of rupture of membranes tests

FDA - U.S. Food and Drug Administration

8-8-2018

Product Quest Manufacturing LLC Issues Voluntary Nationwide Recall of CVS Health 12 Hour Sinus Relief Nasal Mist Due to Microbiological Contamination

Product Quest Manufacturing LLC Issues Voluntary Nationwide Recall of CVS Health 12 Hour Sinus Relief Nasal Mist Due to Microbiological Contamination

Holly Hill, FL, Product Quest Manufacturing (“Product Quest”) is voluntarily recalling Lot# 173089J of CVS Health 12 Hour Sinus Relief Nasal Mist, a clear, colorless liquid, to the consumer level. The product was found to have had microbiological contamination identified as Pseudomonas aeruginosa.

FDA - U.S. Food and Drug Administration

2-8-2018

"Jian Pai Natural Skin Care Cream" contains antifungal drugs not listed on the label, which may pose serious health risks

"Jian Pai Natural Skin Care Cream" contains antifungal drugs not listed on the label, which may pose serious health risks

Health Canada testing of “Jian Pai Natural Skin Care Cream,” also called ‘’Yikangshuang,” found that it contains two antifungal drugs (fluconazole and miconazole) that are not listed on the product label, and may pose serious health risks.

Health Canada

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

6-7-2018

Pseudomonas Aeruginosa Bacteria Found In Saje Splish Splash Gentle Baby Wash

Pseudomonas Aeruginosa Bacteria Found In Saje Splish Splash Gentle Baby Wash

Saje Natural Wellness is warning customers not to use Splish Splash Gentle Baby Wash, 8.5 fl. oz. and 1.7 fl. oz. (found in the Wee and Well Gentle Baby Care Kit) as it may contain the bacteria Pseudomonas aeruginosa. Pseudomonas aeruginosa is an opportunistic pathogen that causes infection and results in bacteria in the blood, particularly in individuals with compromised immune systems.

FDA - U.S. Food and Drug Administration

28-6-2018

June 28, 2018: Southern District of Florida Charges 124 Individuals Responsible for $337 Million in False Billing as Part of National Healthcare Fraud Takedown

June 28, 2018: Southern District of Florida Charges 124 Individuals Responsible for $337 Million in False Billing as Part of National Healthcare Fraud Takedown

June 28, 2018: Southern District of Florida Charges 124 Individuals Responsible for $337 Million in False Billing as Part of National Healthcare Fraud Takedown

FDA - U.S. Food and Drug Administration

19-6-2018

Various Aortic Endovascular Graft Systems: Letter to Health Care Providers - UPDATE on Type III Endoleaks

Various Aortic Endovascular Graft Systems: Letter to Health Care Providers - UPDATE on Type III Endoleaks

Based on new information, the Endologix AFX with Strata device is at greater risk for a Type III endoleak compared to other endovascular AAA graft systems.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

12-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care

FDA - U.S. Food and Drug Administration

2-10-2018

Nexium Control (Pfizer Healthcare Ireland)

Nexium Control (Pfizer Healthcare Ireland)

Nexium Control (Active substance: esomeprazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6474 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/002618/T/0023

Europe -DG Health and Food Safety

2-10-2018

Ritemvia (Celltrion Healthcare Hungary Kft.)

Ritemvia (Celltrion Healthcare Hungary Kft.)

Ritemvia (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)6480 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

27-9-2018

We want to help patients/caregivers know how to use pen needles correctly. FDA received reports of patients using standard pen needles to inject insulin w/o removing the inner needle cover. The cover stopped patients from getting the right amnt of insulin

We want to help patients/caregivers know how to use pen needles correctly. FDA received reports of patients using standard pen needles to inject insulin w/o removing the inner needle cover. The cover stopped patients from getting the right amnt of insulin

We want to help patients/caregivers know how to use pen needles correctly. FDA received reports of patients using standard pen needles to inject insulin w/o removing the inner needle cover. The cover stopped patients from getting the right amnt of insulin https://go.usa.gov/xPWZq  pic.twitter.com/LT9SptJge1

FDA - U.S. Food and Drug Administration

25-9-2018

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices:  http

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices: http

Single use devices should not be reused. Your health care provider or emergency personnel may be able to assist you in obtaining a supply of single use devices during an emergency. Click the link to find out how to safely reuse multiple use devices: https://go.usa.gov/xPjCj  pic.twitter.com/yVSNlc5Qb0

FDA - U.S. Food and Drug Administration

25-9-2018

Pelgraz (Accord Healthcare Limited)

Pelgraz (Accord Healthcare Limited)

Pelgraz (Active substance: pegfilgrastim) - Centralised - Authorisation - Commission Decision (2018)6288 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/003961/0000

Europe -DG Health and Food Safety

24-9-2018

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments:  https://go.usa.gov/xPjKX pic.twitt

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments: https://go.usa.gov/xPjKX pic.twitt

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments: https://go.usa.gov/xPjKX  pic.twitter.com/iQsKIAAQTn

FDA - U.S. Food and Drug Administration

24-9-2018

Blitzima (Celltrion Healthcare Hungary Kft.)

Blitzima (Celltrion Healthcare Hungary Kft.)

Blitzima (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)6228 of Mon, 24 Sep 2018

Europe -DG Health and Food Safety

24-9-2018

Lenalidomide Accord (Accord Healthcare Limited)

Lenalidomide Accord (Accord Healthcare Limited)

Lenalidomide Accord (Active substance: lenalidomide) - Centralised - Authorisation - Commission Decision (2018)6237 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4857

Europe -DG Health and Food Safety

19-9-2018

 12th Pharmacovigilance stakeholder forum, European Medicines Agency, London, UK, From: 24-Sep-2018, To: 24-Sep-2018

12th Pharmacovigilance stakeholder forum, European Medicines Agency, London, UK, From: 24-Sep-2018, To: 24-Sep-2018

This forum brings together regulators with patients, healthcare professionals and industry, to take stock of what we have achieved and what needs to be the focus over the coming years.

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

This Healthcare Professionals' Working Party (HCPWP) plenary meeting will include discussions on advances in clinical practice and the scientific and regulatory challenges. Members will also be invited to present how they are including regulatory sciences in fellowships and young researchers’ training. Feedback will be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

This joint Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) meeting will include results of the 2017 EMA perception survey. EMA regulatory science to 2025 will be discussed together with updates on Good Pharmacovigilance Practices (GVP). The Topic Group on Digital media and health will feedback to the working parties’ members. Participants will also receive an update on ongoing work on electronic product information and on availability of authorised med...

Europe - EMA - European Medicines Agency

7-9-2018

Newsletter:  Human medicines highlights - September 2018

Newsletter: Human medicines highlights - September 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

29-8-2018

Cortacare (Ecuphar NV)

Cortacare (Ecuphar NV)

Cortacare (Active substance: Hydrocortisone aceponate) - Centralised - Authorisation - Commission Decision (2018)5781 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4689

Europe -DG Health and Food Safety

25-8-2018

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety  https://go.usa.g

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety https://go.usa.g

#ICYMI This past week was Healthy Contact Lens Week. The FDA encourages everyone to take care of their contact lenses by proper cleaning, routine exams and visits, and following the FDA and @CDCgov to stay informed on contact lens safety https://go.usa.gov/xUuSb  #OnePairTakeCare pic.twitter.com/hNCAOAmJVQ

FDA - U.S. Food and Drug Administration

24-8-2018

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

FDA - U.S. Food and Drug Administration

23-8-2018

Check out the #FDA’s 7 tips for proper contact lens care #OnePairTakeCarepic.twitter.com/u4VcqcA2uJ

Check out the #FDA’s 7 tips for proper contact lens care #OnePairTakeCarepic.twitter.com/u4VcqcA2uJ

Check out the #FDA’s 7 tips for proper contact lens care #OnePairTakeCare pic.twitter.com/u4VcqcA2uJ

FDA - U.S. Food and Drug Administration

22-8-2018

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevicepic.twitter.com/SQYFz30oFy

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevicepic.twitter.com/SQYFz30oFy

Routine eye exams and visiting your eye doctor will help ensure and maintain healthy eyes for everyone. #OnePairTakeCare #FDA #MedicalDevice pic.twitter.com/SQYFz30oFy

FDA - U.S. Food and Drug Administration

22-8-2018

Do you need to improve your contact lens wear and care habits? Here are some simple tips to help keep your eyes safe! #OnePairTakeCarepic.twitter.com/Gnez9sxXgE

Do you need to improve your contact lens wear and care habits? Here are some simple tips to help keep your eyes safe! #OnePairTakeCarepic.twitter.com/Gnez9sxXgE

Do you need to improve your contact lens wear and care habits? Here are some simple tips to help keep your eyes safe! #OnePairTakeCare pic.twitter.com/Gnez9sxXgE

FDA - U.S. Food and Drug Administration

22-8-2018

Cholib (Mylan IRE Healthcare Ltd)

Cholib (Mylan IRE Healthcare Ltd)

Cholib (Active substance: fenofibrate / simvastatin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5632 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2559/T/20

Europe -DG Health and Food Safety

21-8-2018

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months!  https://go.usa.gov/xUskq 
#OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCare pic.twitter.com/VRDkVPvMTR

FDA - U.S. Food and Drug Administration

21-8-2018

It’s Contact Lens Health Week and the FDA is working to ensure safe and useful devices are available to patients and consumers. Check out our recent contact lens approvals:  https://go.usa.gov/xUz4M  and https://go.usa.gov/xUz4t  #OnePairTakeCarepic.twitt

It’s Contact Lens Health Week and the FDA is working to ensure safe and useful devices are available to patients and consumers. Check out our recent contact lens approvals: https://go.usa.gov/xUz4M  and https://go.usa.gov/xUz4t  #OnePairTakeCarepic.twitt

It’s Contact Lens Health Week and the FDA is working to ensure safe and useful devices are available to patients and consumers. Check out our recent contact lens approvals: https://go.usa.gov/xUz4M  and https://go.usa.gov/xUz4t  #OnePairTakeCare pic.twitter.com/PcxUGHgwoV

FDA - U.S. Food and Drug Administration

21-8-2018

Always use contact lens solution, not water, to clean and store your lenses!  #OnePairTakeCare  https://go.usa.gov/xUs89 pic.twitter.com/Jm50z0UFVu

Always use contact lens solution, not water, to clean and store your lenses! #OnePairTakeCare https://go.usa.gov/xUs89 pic.twitter.com/Jm50z0UFVu

Always use contact lens solution, not water, to clean and store your lenses! #OnePairTakeCare https://go.usa.gov/xUs89  pic.twitter.com/Jm50z0UFVu

FDA - U.S. Food and Drug Administration

20-8-2018

Tune into CDC Facebook today at 2 pm ET for a Facebook Live chat on contact lens wear and care.  https://www.facebook.com/CDC/  #OnePairTakeCarepic.twitter.com/Akf1Dz93Xx

Tune into CDC Facebook today at 2 pm ET for a Facebook Live chat on contact lens wear and care. https://www.facebook.com/CDC/  #OnePairTakeCarepic.twitter.com/Akf1Dz93Xx

Tune into CDC Facebook today at 2 pm ET for a Facebook Live chat on contact lens wear and care. https://www.facebook.com/CDC/  #OnePairTakeCare pic.twitter.com/Akf1Dz93Xx

FDA - U.S. Food and Drug Administration

20-8-2018

Contact Lens Health Week is here and the FDA and @CDCgov are reminding you of safe measures to ensure proper use of contact lenses. Check out the CDC’s Healthy Habits Mean Healthy Eye video #OnePairTakeCarepic.twitter.com/jxiBHA3CiT

Contact Lens Health Week is here and the FDA and @CDCgov are reminding you of safe measures to ensure proper use of contact lenses. Check out the CDC’s Healthy Habits Mean Healthy Eye video #OnePairTakeCarepic.twitter.com/jxiBHA3CiT

Contact Lens Health Week is here and the FDA and @CDCgov are reminding you of safe measures to ensure proper use of contact lenses. Check out the CDC’s Healthy Habits Mean Healthy Eye video #OnePairTakeCare pic.twitter.com/jxiBHA3CiT

FDA - U.S. Food and Drug Administration

17-8-2018

Next week is Healthy Contact Week. Join the @CDCgov for a Facebook Live chat on Monday August 20th at 2 PM for a conversation on contact lens use.  http://facebook.com/CDC/   #OnePairTakeCarepic.twitter.com/7HDQYrdPBv

Next week is Healthy Contact Week. Join the @CDCgov for a Facebook Live chat on Monday August 20th at 2 PM for a conversation on contact lens use. http://facebook.com/CDC/  #OnePairTakeCarepic.twitter.com/7HDQYrdPBv

Next week is Healthy Contact Week. Join the @CDCgov for a Facebook Live chat on Monday August 20th at 2 PM for a conversation on contact lens use. http://facebook.com/CDC/  #OnePairTakeCare pic.twitter.com/7HDQYrdPBv

FDA - U.S. Food and Drug Administration

17-8-2018

#FDA issues letter to healthcare providers on the final post-approval study results & risks associated with #SynCardia TAH-t: C2 Driver System.  https://go.usa.gov/xUeYd  #MedicalDevices

#FDA issues letter to healthcare providers on the final post-approval study results & risks associated with #SynCardia TAH-t: C2 Driver System. https://go.usa.gov/xUeYd  #MedicalDevices

#FDA issues letter to healthcare providers on the final post-approval study results & risks associated with #SynCardia TAH-t: C2 Driver System. https://go.usa.gov/xUeYd  #MedicalDevices

FDA - U.S. Food and Drug Administration

8-8-2018

Letter to Health Care Providers: Risks Associated with Use of Rupture of Membrane Tests   https://go.usa.gov/xUAt4  #MedicalDevice #FDA

Letter to Health Care Providers: Risks Associated with Use of Rupture of Membrane Tests https://go.usa.gov/xUAt4  #MedicalDevice #FDA

Letter to Health Care Providers: Risks Associated with Use of Rupture of Membrane Tests https://go.usa.gov/xUAt4  #MedicalDevice #FDA

FDA - U.S. Food and Drug Administration

7-8-2018

Accofil (Accord Healthcare Limited)

Accofil (Accord Healthcare Limited)

Accofil (Active substance: Filgrastim) - Centralised - Yearly update - Commission Decision (2018)5428 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

7-8-2018

Memantine Accord (Accord Healthcare Limited)

Memantine Accord (Accord Healthcare Limited)

Memantine Accord (Active substance: memantine) - Centralised - Renewal - Commission Decision (2018)5421 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2766/R/10

Europe -DG Health and Food Safety

6-8-2018

Human medicines highlights - August 2018

Human medicines highlights - August 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

6-8-2018

Zoledronic acid Accord (Accord Healthcare Limited)

Zoledronic acid Accord (Accord Healthcare Limited)

Zoledronic acid Accord (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)5386 of Mon, 06 Aug 2018

Europe -DG Health and Food Safety

23-7-2018

Rituzena (Celltrion Healthcare Hungary Kft.)

Rituzena (Celltrion Healthcare Hungary Kft.)

Rituzena (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)4884 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

18-7-2018

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity:  https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://healthsectorcouncil.org/health-sector-mobilizes-against-cyber-threats/ …

FDA - U.S. Food and Drug Administration

13-7-2018

Vizamyl (GE Healthcare Ltd)

Vizamyl (GE Healthcare Ltd)

Vizamyl (Active substance: flutemetamol (18F)) - Centralised - Yearly update - Commission Decision (2018)4614 of Fri, 13 Jul 2018

Europe -DG Health and Food Safety

10-7-2018

Human medicines highlights - July 2018

Human medicines highlights - July 2018

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Europe - EMA - European Medicines Agency

4-7-2018

Docetaxel Accord (Accord Healthcare Limited)

Docetaxel Accord (Accord Healthcare Limited)

Docetaxel Accord (Active substance: Docetaxel) - Centralised - Yearly update - Commission Decision (2018)4341 of Wed, 04 Jul 2018

Europe -DG Health and Food Safety

3-7-2018

Temozolomide Accord (Accord Healthcare Limited)

Temozolomide Accord (Accord Healthcare Limited)

Temozolomide Accord (Active substance: temozolomide) - Centralised - Yearly update - Commission Decision (2018) 4240 of Tue, 03 Jul 2018

Europe -DG Health and Food Safety

27-6-2018

Nexium Control (Pfizer Consumer Healthcare Limited)

Nexium Control (Pfizer Consumer Healthcare Limited)

Nexium Control (Active substance: esomeprazole) - Centralised - Renewal - Commission Decision (2018) 4111 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2618/R/21

Europe -DG Health and Food Safety